본문 바로가기

Pipeline

(* You can scroll left and right)

이 표는 수집하는 개인정보 항목 및 수집방법, 개인정보의 수집목적 및 이용목적, 개인정보의 공유 및 제공, 수집한 개인정보 처리 위탁, 수집한 개인정보의 보유 및 이용기간, 개인정보 파기절차 및 방법, 이용자 및 법정대리인의 권리와 그 행사방법, 쿠키의 운영과 활용(자동수집장치 설치, 운영, 거부에 관한 사항), 개인정보 보호를 위한 이용자의 주의사항, 개인정보 관리 책임자, 부칙 구성되어 있습니다.
Therapeutic Area Project Code Target Indication Development Stage
Lead NME Clinical NDA Product
Liver Disease BESIVO Hepatitis B  
ID119031166 NASH  
ID119050134 Hepatic cirrhosis  
CNS lasmiditan Migraine  
Oncology venadaparib Breast Cancer  
ID11902 Solid Tumor  
ID11916 Breast Cancer  
Metabolic Disease IDG16177 Type-2 Diabetes  
ID110521156 Type-2 Diabetes  
Ophthalmology IDB0062 Wet AMD  
ID110410395 Dry Eye Disease  
ID119010018 Glaucoma  
Respiratory Disease ID119010023 Respiratory diseases  
Gastrointestinal Disease ID120040002 GERD

Liver Disease
ID119031166

• A potent non-steroidal FXR agonist to treat NASH:
 - Mechanism of action that inhibits the synthesis of bile acid
 - Strong activity and selectivity demonstrated in nonclinical studies
 - Significantly reduced NAFLD Activity score and fibrosis in animal models of NASH
 - Regulated direct FXR target genes in a dose-dependent manner in vivo
 - Not importantly altered plasma level of ALT/AST and LDL-C at the effective dose
• IND submission expected in Q2 2022

NASH : NonAlcoholic SteatoHepatitis, NAFLD : NonAlcoholic Fatty Liver Disease,
FXR : Farnesoid X Receptor, ALT : Alanine aminotransferase,
AST : Aspartate aminotransferase, LDL-C : Low-Density Lipoprotein Cholesterol

close

CNS
LASMIDITAN

• Migraine therapy with an innovative mechanism of action with no restrictions on use in cardiovascular disease patients
 - The first and only Ditan drug approved by the FDA with a different mechanism from triptans (serotonin 1B receptor agonists) and NSAIDs, which have been used as migraine treatments.
 - Overcoming the limitations of existing triptans (limited use in cardiovascular patients) by exhibiting 470-fold or more affinity for serotonin 1F receptors compared to serotonin 1B and 1D receptors associated with vasoconstriction
• NDA submitted in Korea in Q1 2021

NSAIDs : Non-steroidal anti-inflammatory drugs

close

Metabolic Disease
IDG16177

• A GPR40 agonist to treat type 2 diabetes mellitus
 - High oral absolute bioavailability in pre-clinical species
 - A defined MoA, activating β-arrestin2 recruitment as well as Gq-dependent pathway
 - Glucose-dependent insulin secretion & free of hypoglycemic risk
 - Superior to fasiglifam in glucose reduction in normal and diabetic rat studies
 - Potentially no risk of DILI (drug-induced liver injury)
Phase 1 has started in Germany in July 2021 to evaluate safety and pharmacokinetics (NCT04982705)

close

Metabolic Disease
ID110521156

•A small-molecule glucagon-like peptide (GLP)-1 receptor agonist to treat type 2 diabetes
 - Being developed as an oral drug
 - Overcame the disadvantages of existing injection drugs (improved safety profile and
    patient adherence)
 - Potential of expansion to various indications including NASH and Obesity
• IND submission expected in Q1 2023

GLP-1 : Glucagon-like peptide-1, NASH : NonAlcoholic SteatoHepatitis

close

Ophthalmology
IDB0062

• A dual-targeting antibody fragment drug for wet AMD
 - A VEGF-A/NRP1 dual-targeting antibody fragment engineered through tissue-penetrating
    peptide technology
 - Enhanced efficacy by inhibiting multiple pro-angiogenic growth factors
 - Targets bi- to tri-monthly dosing interval based on improved ocular PK 
 - Possibility of non-invasive drug administration through tissue-penetrating peptides
• No known systemic safety issues by GLP tox study​
• Pre-clinical development accelerated through Lonza’s CMC platform
• Accelerating CMC development with Global CDMO

Ophthalmology
ID110410395

• First-in-class small molecule CFTR activator to treat dry eye disease
 - has a novel mode of action to increase tear secretion
 - targets to improve both signs and symptoms with favorable tolerability profile and simplified dosing
• IND submission expected in Q4 2022

CFTR : Cystic Fibrosis Transmembrane Regulator

close

Ophthalmology
ID119010018

• A nitric oxide-donating PDE5 inhibitor for Glaucoma
 - Metabolized in the body to release nitric oxide and at the same time inhibits PDE5/6 to
     increase PKG (protein kinase G) activity
 - Activates PKG by increasing the amount of cGMP by inhibiting the degradation of cGMP
 - Activated PKG relaxes smooth muscle and increases blood flow

cGMP : Cyclic Guanosine MonoPhosphate

close

Respiratory Disease
ID119010023

• A nitric oxide-donating PDE5 inhibitor for ARDS, PAH
 - Highly selective and potent in vitro activity
 - Efficacy shown in an acute lung injury mouse model
• in vivo efficacy study, formulation, PK analysis are on-going
• IND submission expected in 1Q 2023

ARDS : Acute Respiratory Distress Syndrome, PDE5 : PhosphoDiEsterase 5

close

* HBV polymerase inhibitor : Regulatory approval in Korea in May 2017 The 28th domestic new drug

* GPR40 agonist : Clinical Trial Application (CTA) approval in June 2021 in Germany

최상단으로 바로가기